Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2020 Apr 23.
Published in final edited form as: Neurosci Lett. 2019 Jan 29;699:54–58. doi: 10.1016/j.neulet.2019.01.046

Spinal macrophage migration inhibitory factor and high mobility group box 1 mediate persistent bladder pain

Fei Ma 1,2, Katherine L Meyer-Siegler 3, Lin Leng 4, Richard Bucala 4, Pedro L Vera 1,2
PMCID: PMC6443422  NIHMSID: NIHMS1520662  PMID: 30708129

Abstract

Repeated intravesical PAR4 (protease activated receptor 4) activation elicits persistent bladder pain lasting 5 days after the last treatment. Persistent bladder pain was fully reversed by a systemic HMGB1 (high mobility box 1) inhibitor while a MIF (macrophage migration inhibitory factor) antagonist partly reversed it. Since there is growing evidence that spinal MIF and HMGB1 mediate inflammatory and neuropathic pain we examined whether there were spinal changes occurring during persistent bladder pain that may be responsible for maintaining bladder pain. In addition, we tested whether we could modulate persistent bladder pain with spinal MIF or HMGB1 antagonists. Persistent bladder pain was elicited in female C57 mice by repeated (3x) intravesical instillation of PAR4-activating peptide while control animals received scramble peptide treatment. On day 4, spinal cord (L6-S1) changes in c-fos (non-specific marker of spinal activation) was assessed with immunofluorescence while MIF and HMGB1 were assessed with immunofluorescence, western blotting and real-time PCR. On day 7, mice received an intrathecal injection of a neutralizing MIF monoclonal antibody (15 μg in 5 μl PBS) or a HMGB1 inhibitor glycyrrhizin (25 μg in 5 μl of 5 % alcohol in PBS) and abdominal mechanical threshold was tested. On day 9, mice were treated with vehicle or control and abdominal mechanical threshold was tested. Immunofluorescence showed that c-fos and MIF in the dorsal horn, dorsal grey commissure and intermediolateral areas significantly increased in PAR4-treated mice while HMGB1 was decreased. In addition, intrathecal treatment with MIF neutralizing mAb or glycyrrhizin significantly alleviated abdominal mechanical hypersensitivity at 1 and 2 hours and the analgesic effect diminished at 6 hours. Vehicle or control treatment had no effect. Persistent bladder pain is associated with spinal changes in MIF and HMGB1 levels. Furthermore, spinal treatment with MIF monoclonal antibody and HMGB1 inhibitor temporarily reversed bladder pain. Our findings suggest that spinal MIF and HMGB1 participate in persistent bladder pain induced by repeated intravesical PAR4 and may be potential therapeutic targets in chronic bladder pain conditions.

Keywords: persistent bladder pain, MIF, HMGB1, PAR4, Intrathecal

Introduction

We previously reported that intravesical instillation of protease activated receptor 4 (PAR4) activating peptide (AP) causes abdominal mechanical hypersensitivity, an indicator of bladder pain [10]. The bladder pain lasted 24 hours after PAR4 instillation and minimal bladder histological change were detected. In this model, macrophage migration inhibitory factor (MIF) was released from bladder urothelium which promoted high mobility group box 1 (HMGB1) release from bladder urothelium and then triggered bladder pain [9, 10, 15].

MIF is a proinflammatory mediator initiating inflammatory processes and playing a critical role in inflammation-induced pain [7, 23]. Mounting evidence shows that MIF itself also mediates pain [2, 10]. Either nerve injury induced neuropathic pain or lipopolysaccharide (LPS)-induced bladder pain increased MIF expression in spinal cord [19, 24]. Intrathecal injection of MIF inhibitor or antiserum blocked nerve injury induced neuropathic pain indicating that spinal MIF mediates persistent pain [24].

HMGB1, a DNA binding protein, was recently found to be actively released from nuclei to cytoplasm then to the extracellular space to be involved in inflammation [8]. There are accumulating reports that spinal HMGB1 and its receptor toll like receptor 4 (TLR4) facilitated persistent pain processing through spinal glial cells [1, 6]. Moreover, involvement of spinal HMGB1 and TLR4 in visceral pain has been shown in colitis and pancreatitis [5, 25].

Recently, we developed a persistent bladder pain model by repeated intravesical installation of PAR4 (3x, 48 hours apart) and bladder pain was maintained 5 days after last intravesical treatment [14]. No overt histological signs of inflammation were shown in the afflicted bladders indicating that the bladder pain maintenance is independent of direct bladder injury and that bladder pain persisted after bladder injury resolution.

The present study investigated the central mechanisms of persistent bladder pain focusing on the involvement of spinal MIF and HMGB1.

Material and methods

All animal experiments were approved by the Lexington Veterans Affairs Medical Center Institutional Animal Care and Use Committee (VER-11–016-HAF) and performed according to the guidelines of the National Institutes of Health.

Abdominal mechanical hypersensitivity test

Female C57BL/6 (SPF, 13 – 17-week-old; 20–25 g; Jackson Laboratory, Bar Harbor, ME) were housed in ventilated animal cages with 14/10 light/dark cycle and free access to water and food (Teklad 8626).

Repeated intravesical instillation of PAR4 to induce persistent bladder pain was previously described [14]. Briefly, PAR4-AP or PAR4-scrambled peptide as control (100 μM in PBS; 150 μl; Peptides International, Louisville, KY) were instilled into the mouse bladder lumen under isoflurane anesthesia and held for 1 hour. Intravesical instillation occurred on day 0, 2 and 4 for a total of three intravesical instillations. Abdominal mechanical hypersensitivity was tested in mice by recording 50% mechanical threshold as described [14]. Briefly, mechanical threshold was measured with eight von Frey fibers (0.008, 0.02, 0.07, 0.16, 0.4, 1.0, 2.0 and 6.0 g). Whenever a positive response to a stimulus occurred, the next smaller von Frey filament was applied. Otherwise, the next higher filament was applied to detect the mechanical threshold. Positive response was defined as any one of three behaviors: 1) licking the abdomen, 2) flinching/jumping, or 3) abdomen withdrawal. Abdominal mechanical hypersensitivity lasted 9 days after first instillation in the persistent bladder pain. In a group of mice (PAR4-treated, N=6; Scramble-treated, N=6), L6-S1 spinal cords were extracted on day 5 after the first intravesical injection for immunohistochemistry, real-time PCR and western blotting analysis.

Intrathecal administration

On day 7 after first intravesical instillation, the mouse was placed under isoflurane anesthesia and the spinal lumbar region was held firmly. A 25 μl Hamilton syringe with a 30-gauge needle was inserted between L5 and L6 until the intrathecal space was reached as indicated by tail twitch and then 5 μl (treatments or vehicle control) were injected [17]. MIF monoclonal antibody (mAb) (15 μl in 5 μl PBS; N=6) [12] or Glycyrrhizin (5 μg/μl in 5% EtoH of PBS; 356780, Calbiochem; Burlington, MA; N=5) was intrathecally injected. On day 9 mice received intrathecal injections of isotype mAb (Mouse IgG1) as control for MIF mAb (15 μl in 5 μl PBS) [12] or vehicle as control for glycyrrhizin. Mice were allowed to recover from anesthesia for 1 hour after intrathecal injections. Behavioral changes were measured by von Frey at 1, 2, 4, 8 and 24 hours after intrathecal injection.

Immunohistochemistry

Frozen L6-S1 spinal cord sections were blocked (5% goat serum, 0.2% Triton X-100 in PBS, 30 min at room temp.), then incubated overnight at 4°C with rabbit polyclonal anti-c-fos antibody (1:500; 226003; Synaptic system, Goettingen, Germany), goat polyclonal anti-MIF antibody (1:100; AF-289-PB; R&D; Minneapolis, MN), rabbit polyclonal anti-HMGB1 antibody (1:100; ab18256; Abcam, Cambridge, MA). Non-specific (goat or rabbit) IgG were used as controls. Immunoreactivity was detected with donkey anti-goat or donkey anti-rabbit FITC-labeled secondary antibody (1:100 in PBS with 1% goat serum, 0.2% Triton X-100; 1 hour at room temp.; Jackson ImmunoResearch, Inc., West Grove, PA) before cover-slipping (Vectashield, Vector Laboratories, Burlingame, CA). We examined areas that receive bladder afferent information: the dorsal horn (DH), dorsal gray commissure (DC) and the intermediolateral area (IML) in L6-S1 spinal cord [20]. Computer-assisted densitometry of HMGB1 immunostaining intensity and cell counts of positive c-fos and MIF were performed on images captured using a LEICA DMI4000B microscope equipped with the LAS V4 program and ImageJ (NIH, Bethesda, MD).

Real-time PCR

Total RNA was extracted from L6-S1 spinal cord of PAR4- or scramble-treated mice through Trizol (15596026, ThermoFisher Scientific, Grand Island, NY), DNA removed by DNase, and reversed transcribed to cDNA (A3500, Promega, Madison, WI). PCR products were detected using SYBR green (4472903, ThermoFisher Scientific, Grand Island, NY) binding with primers (MIF, PPM02985H; HMGB1, PPM05059F; GAPDH, PPM02946E, Qiagen, Germantown, MD) to quantify levels of mRNA in spinal tissue from two groups of mice. Detection of GAPDH PCR product was used as the internal control.

Western blotting

Proteins extracted from L6-S1 spinal cord PAR4- or scramble-treated mice were separated using a 4 – 15% Mini-PROTEAN TGX precast polyacrylamide gel (Bio-Rad, Hercules, CA). After electrophoresis, separated proteins were transferred to a polyvinylidene difluoride membrane. MIF and HMGB1 protein bands were visualized using a biotinylated goat polyclonal primary antibody (BAF289; R&D, Minneapolis, MN; 1:1000) and a rabbit polyclonal primary antibody (ab18256; Abcam, Cambridge, MA; 1:4000), along with GAPDH as an internal control (A00915, GenScript, Piscataway, NJ; 1:2500), a biotinylated anti-rabbit secondary antibody (Vector Labs, Burlingame, CA; 1:400), streptavidin-HRP conjugates and chemiluminescent substrate (Pierce, Rockford, IL). Band densitometry was performed using ImageJ (NIH, Bethesda, MD).

Statistical analyses

All parameters are reported as mean ± SE. Changes in 50% mechanical threshold to von Frey stimulation were determined by comparing mechanical threshold at different time points and analyzed using Tukey tests. Changes in immunohistochemistry, real-time PCR and western blotting were analyzed using one-way ANOVA. All statistical analyses were conducted using R [21].

Results

Spinal c-fos, MIF and HMGB1 changes in persistent bladder pain.

Immunofluorescence showed that c-fos positive cells were increased in PAR4-treated mice compared with scramble-treated mice in DC (26.0 ± 3.2 vs. 14.0 ± 4.1, p < 0.05; Fig 1A; B show representative sections), DH (11.2 ± 1.2 vs. 3.3 ± 0.8, p < 0.001) and IML (9.7 ± 1.3 vs. 4.5 ± 1.0, p < 0.05) of spinal L6-S1 (Fig. 1C). PAR4-treated mice also showed higher number of positively stained MIF cells in DC (40.5 ± 4.5 vs. 12.8 ± 2.6, p < 0.001), DH (48.8 ± 4.0 vs. 11.7 ± 1.8, p < 0.001) and IML (14.2 ± 1.5 vs. 6.8 ± 0.8, p < 0.01; Fig 1D; E show representative sections) of spinal L6-S1 (Fig. 1F) compared with scramble-treated mice (Fig. 1D). HMGB1 immunofluorescent intensities were significantly decreased in PAR4-treated mice compared with scramble-treated mice in DC (8.1 ± 0.9 vs. 12.8 ± 0.8, p < 0.01), DH (10.7 ± 0.8 vs. 15.1 ± 1.0, p < 0.01; Fig 1G; H show representative sections) and IML (6.9 ± 0.9 vs. 13.9 ± 1.1, p < 0.001) of spinal L6-S1 (Fig. 1I).

Figure 1. Spinal c-fos, MIF and HMGB1 changes after repeated PAR4 instillations.

Figure 1.

Changes in c-fos, MIF and HMGB1 after repeated intravesical PAR4 scramble (N=6; control) or activating peptide (N=6) were detected by immunofluorescence in spinal DC, IML and DH which receive bladder afferent information. (A) There was minimal c-fos expression in DC after repeated scramble instillations. (B) c-fos expression was increased in DC after repeated intravesical PAR4. (C) Histogram showing that c-fos positive cells were significantly increased in all three areas of spinal cord after repeated PAR4 instillations compared to scramble-treated group. (D) MIF expression in IML was low in scramble group. (E) Repeated intravesical PAR4 increased MIF expression in IML. (F) Histogram showing that MIF positively immuno-stained cells were significantly increased in all three areas of spinal cord after repeated PAR4 instillations compared with scramble group. (G) HMGB1 was localized to nearly every cell in DH (and other areas of the spinal cord) of scramble-treated group. (H) HMGB1 immunofluorescent intensity was decreased in DH after repeated intravesical PAR4. (I) Histogram showed that HMGB1 immunofluorescent intensity units were significantly decreased in all three areas of spinal cord after repeated PAR4 instillations compared with scramble group. *p < 0.05, **p < 0.01, ***p < 0.001 vs. scramble group

Spinal L6-S1 levels of MIF and HMGB1 mRNA and protein were examined in both scramble-treated and PAR4-treated mice. Real-time PCR results showed no differences in levels of MIF or HMGB1 mRNA in scramble and PAR4 groups when normalized to 18S rRNA (p > 0.05). Similarly, protein levels of spinal L6-S1 MIF and HMGB1 (tested by western blot) also showed no changes between the two groups (Data not shown).

Persistent bladder pain alleviation by spinal MIF and HMGB1 inhibition

Abdominal mechanical hypersensitivity was elicited after repeated PAR4-treatment (Fig 2; red arrows indicated intravesical treatments) as we reported earlier [14]. Spinal administration of neutralizing MIF mAb partially reversed persistent bladder pain at 1 hour post-intrathecal injection (0.074 ± 0.017 vs. 0 hour 0.002 ± 0.001, p < 0.01) and the effect peaked at 2 hours (0.141 ± 0.02, p < 0.001). The analgesic effect was reduced at 4 hours (0.071 ± 0.016, p < 0.01) and diminished at 6 hours (0.017 ± 0.006, p > 0.05) (Fig. 2A, inset 1). Spinal administration of control mouse IgG1 had no effect on mechanical hypersensitivity (Fig. 2A, inset 2).

Figure 2. Analgesia by intrathecal MIF and HMGB1 inhibition in persistent bladder pain.

Figure 2.

Repeated intravesical PAR4 (day 0, 2 and 4; indicated by red arrows) significantly decreased mechanical threshold one day after first injection and then the mechanical hypersensitivity lasted until day 9. Mechanical threshold changes were tested at 1, 2, 4 and 6 hours after intrathecal injection of neutralizing MIF mAb or HMGB1 inhibitor glycyrrhizin on day 7 and controls (IgG1 or vehicle) on 9 after first PAR4 instillation. (A) Intrathecal MIF mAb (15 μg) significantly increased mechanical threshold at 1 hour after injection and the analgesic effect peaked at 2 hours. Analgesia persisted for 4 hours and diminished at 6 hours (inset 1). Intrathecal IgG1 had no effect on mechanical hypersensitivity within 6 hours testing period (inset 2). (B) Intrathecal glycyrrhizin (GLY, 25 μg) significantly increased mechanical threshold and reached the highest analgesic effect at 1 hour after injection. Analgesic effect lasted for 4 hours and disappeared at 6 hours (inset 1). Vehicle (Veh) did not have effect on mechanical hypersensitivity within 6 hours after intrathecal injection (inset 2). **p < 0.01, ***p < 0.001 vs. 0 hour

Similarly, a HMGB1 inhibitor glycyrrhizin (GLY, 25 μg in PBS with 5% alcohol) was intrathecally injected and mechanical threshold was tested. The persistent bladder pain was alleviated and the effect peaked at 1 hour (0.12 ± 0.008 vs. before i.t. injection 0.003 ± 0.002, p < 0.001). The analgesic effect was reduced at 2 hours (0.096 ± 0.007, p < 0.001) and 4 hours (0.043 ± 0.007, p < 0.01) and diminished at 6 hours (0.002 ± 0.001, p > 0.05) (Fig. 2B, inset 1). Glycyrrhizin vehicle control (Veh) did not have effect on mechanical hypersensitivity (Fig. 2B, inset 2).

Discussion

We previously showed that a single intravesical injection of PAR4 caused bladder hypersensitivity that lasted only 24 hours without overt sign of bladder inflammation [10]. This acute effect was due to a single and mild injury to the bladder urothelium since no overt histological signs of inflammation were noted (e.g. edema; infiltrating cells) [9, 10]. We extended our findings using a mouse model of persistent bladder pain that showed the abdominal mechanical hypersensitivity (referred bladder pain) persisted for 5 days after the last bladder stimulus and in absence of bladder injury or bladder inflammation [14]. Mechanisms other than bladder effects may participate in this model of persistent bladder pain. The previous systemic application of either MIF or HMGB1 inhibition partially or completely reversed persistent bladder pain however the site action, peripheral (organ level) or central (spinal level) still needed to be determined. Our current results show that c-fos, a non-specific marker of spinal activation [4] was increased in areas of L6/S1 spinal cord that receive bladder afferent information [3]. Previous investigators have demonstrated c-fos increases in these same areas in other models of bladder cystitis that also elicit bladder pain [3, 22]. Therefore, our results indicate spinal activation during persistent bladder pain in our model.

Moreover, MIF was increased while HMGB1 was decreased during persistent bladder pain in areas of the L6-S1 spinal cord that receive bladder afferent information indicating that both MIF and HMGB1 may participate in the bladder pain induced by repeated PAR4 instillations. Spinal HMGB1 decrease in persistent bladder pain may suggest release of HMGB1 into the extracellular space after MIF activation and this agrees with our previous result that urothelial HMGB1 release induced by MIF in acute PAR4-induced bladder pain [9]. Additionally, MIF-mediated HMGB1 release was described in vitro [13]. No changes were found in spinal MIF and HMGB1 by real-time PCR and western blotting. A likely explanation is that differences in discrete areas of the spinal cord (as documented with immunofluorescence) were masked when examining whole spinal cord segments.

Our results also show that the abdominal mechanical hypersensitivity was temporarily reversed by intrathecal administration of either a neutralizing MIF mAb or a HMGB1 inhibitor (glycyrrhizin), suggesting both spinal MIF and HMGB1 mediate persistent bladder pain. Thus, our initial findings using systemic MIF and HMGB1 antagonists to reduce persistent bladder pain [15] are confirmed and the site of action is shown to be the lumbosacral spinal cord.

These results add to the evidence that spinal MIF and/or HMGB1 participate in mediating pain. Spinal MIF was increased after different irritants to the bladder [11, 19] and intrathecal either MIF inhibitor ISO-1 or MIF mAb reversed both inflammation and neuropathy induced mechanical hypersensitivity in hind paws [23, 24]. Spinal HMGB1 and its receptor TLR4 have been shown to mediate somatic hypersensitivity and colitis-induced visceral sensitization [5, 16, 18]. Overall, our results and those of others increase the evidence for spinal MIF and HMGB1 in mediating pain, including persistent bladder pain.

Conclusions

Persistent bladder pain is associated with spinal changes in MIF and HMGB1 levels and spinal treatment with a neutralizing MIF mAb or HMGB1 inhibitor temporarily reversed bladder pain. The present study concludes that spinal MIF and HMGB1 mediate persistent bladder pain induced by repeated intravesical PAR4. MIF and HMGB1 represent novel potential therapeutic targets in chronic bladder pain conditions.

Highlights.

  • Persistent bladder pain is associated with spinal changes in MIF HMGB1 levels.

  • Spinal MIF mediates repeated PAR4 instillation induced persistent bladder pain.

  • Spinal HMGB1 mediates repeated PAR4 instillation induced persistent bladder pain.

Acknowledgements

This study is funded by NIH (DK0093496, PLV; AR049610, RB). The material is the result of work supported with the resources and facilities at the Lexington (Kentucky) Veterans Affairs Health Care System.

Abbreviations

PAR4

protease activated receptor 4

PAR4-AP

PAR4-activating peptide

MIF

macrophage migration inhibitory factor

HMGB1

high mobility group box 1

TLR4

toll like receptor 4

mAb

monoclonal antibody

Footnotes

Conflicts of Interest

The authors declare that there are no conflicts of interest.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Reference

  • [1].Agalave NM, Larsson M, Abdelmoaty S, Su J, Baharpoor A, Lundback P, Palmblad K, Andersson U, Harris H, Svensson CI, Spinal HMGB1 induces TLR4-mediated long-lasting hypersensitivity and glial activation and regulates pain-like behavior in experimental arthritis, Pain 155 (2014) 1802–1813. [DOI] [PubMed] [Google Scholar]
  • [2].Alexander JK, Cox GM, Tian JB, Zha AM, Wei P, Kigerl KA, Reddy MK, Dagia NM, Sielecki T, Zhu MX, Satoskar AR, McTigue DM, Whitacre CC, Popovich PG, Macrophage migration inhibitory factor (MIF) is essential for inflammatory and neuropathic pain and enhances pain in response to stress, Exp Neurol 236 (2012) 351–362. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [3].Birder LA, de Groat WC, Increased c-fos expression in spinal neurons after irritation of the lower urinary tract in the rat, J Neurosci 12 (1992) 4878–4889. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [4].Birder LA, de Groat WC, Induction of c-fos expression in spinal neurons by nociceptive and nonnociceptive stimulation of LUT, Am J Physiol 265 (1993) R326–333. [DOI] [PubMed] [Google Scholar]
  • [5].Chen ZY, Zhang XW, Yu L, Hua R, Zhao XP, Qin X, Zhang YM, Spinal toll-like receptor 4-mediated signalling pathway contributes to visceral hypersensitivity induced by neonatal colonic irritation in rats, Eur J Pain 19 (2015) 176–186. [DOI] [PubMed] [Google Scholar]
  • [6].Christianson CA, Dumlao DS, Stokes JA, Dennis EA, Svensson CI, Corr M, Yaksh TL, Spinal TLR4 mediates the transition to a persistent mechanical hypersensitivity after the resolution of inflammation in serum-transferred arthritis, Pain 152 (2011) 2881–2891. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [7].Flaster H, Bernhagen J, Calandra T, Bucala R, The macrophage migration inhibitory factor-glucocorticoid dyad: regulation of inflammation and immunity, Mol Endocrinol 21 (2007) 1267–1280. [DOI] [PubMed] [Google Scholar]
  • [8].Kato J, Svensson CI, Role of extracellular damage-associated molecular pattern molecules (DAMPs) as mediators of persistent pain, Prog Mol Biol Transl Sci 131 (2015) 251–279. [DOI] [PubMed] [Google Scholar]
  • [9].Kouzoukas DE, Ma F, Meyer-Siegler KL, Westlund KN, Hunt DE, Vera PL, Protease-Activated Receptor 4 Induces Bladder Pain through High Mobility Group Box-1, PLoS One 11 (2016) e0152055. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [10].Kouzoukas DE, Meyer-Siegler KL, Ma F, Westlund KN, Hunt DE, Vera PL, Macrophage Migration Inhibitory Factor Mediates PAR-Induced Bladder Pain, PLoS One 10 (2015) e0127628. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [11].Lee KW, Kim WB, Lee SW, Kim JH, Kim JM, Kim YH, Kim ME, Alterations of Macrophage Migration Inhibitory Factor Expression in the Nervous System of the Rat Cystitis Model, Urol Int 98 (2017) 228–235. [DOI] [PubMed] [Google Scholar]
  • [12].Leng L, Chen L, Fan J, Greven D, Arjona A, Du X, Austin D, Kashgarian M, Yin Z, Huang XR, Lan HY, Lolis E, Nikolic-Paterson D, Bucala R, A small-molecule macrophage migration inhibitory factor antagonist protects against glomerulonephritis in lupus-prone NZB/NZW F1 and MRL/lpr mice, J Immunol 186 (2011) 527–538. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [13].Lv W, Chen N, Lin Y, Ma H, Ruan Y, Li Z, Li X, Pan X, Tian X, Macrophage migration inhibitory factor promotes breast cancer metastasis via activation of HMGB1/TLR4/NF kappa B axis, Cancer Lett 375 (2016) 245–255. [DOI] [PubMed] [Google Scholar]
  • [14].Ma F, Hunt DE, Leng L, Bucala R, Meyer-Siegler KL, Vera PL, Protease activated-receptor 4 activation as a model of persistent bladder pain: Essential role of macrophage migration inhibitory factor and high mobility group box 1, Int J Urol 25 (2018) 887–893. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [15].Ma F, Kouzoukas DE, Meyer-Siegler KL, Hunt DE, Leng L, Bucala R, Vera PL, Macrophage migration inhibitory factor mediates protease-activated receptor 4-induced bladder pain through urothelial high mobility group box 1, Physiol Rep 5 (2017). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [16].Ma YQ, Chen YR, Leng YF, Wu ZW, Tanshinone IIA Downregulates HMGB1 and TLR4 Expression in a Spinal Nerve Ligation Model of Neuropathic Pain, Evid Based Complement Alternat Med 2014 (2014) 639563. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [17].Mamet J, Klukinov M, Yaksh TL, Malkmus SA, Williams S, Harris S, Manning DC, Taylor BK, Donahue RR, Porreca F, Xie JY, Oyarzo J, Brennan TJ, Subieta A, Schmidt WK, Yeomans DC, Single intrathecal administration of the transcription factor decoy AYX1 prevents acute and chronic pain after incisional, inflammatory, or neuropathic injury, Pain 155 (2014) 322–333. [DOI] [PubMed] [Google Scholar]
  • [18].Matsuura W, Harada S, Liu K, Nishibori M, Tokuyama S, Evidence of a role for spinal HMGB1 in ischemic stress-induced mechanical allodynia in mice, Brain Res 1687 (2018) 1–10. [DOI] [PubMed] [Google Scholar]
  • [19].Meyer-Siegler KL, Ordorica RC, Vera PL, Macrophage migration inhibitory factor is upregulated in an endotoxin-induced model of bladder inflammation in rats, J Interferon Cytokine Res 24 (2004) 55–63. [DOI] [PubMed] [Google Scholar]
  • [20].Morgan C, Nadelhaft I, de Groat WC, The distribution of visceral primary afferents from the pelvic nerve to Lissauer’s tract and the spinal gray matter and its relationship to the sacral parasympathetic nucleus, J Comp Neurol 201 (1981) 415–440. [DOI] [PubMed] [Google Scholar]
  • [21].R Core Team, R: A Language and Environment for Statistical Computing, R Foundation for Statistical Computing, Vienna, Austria: (2017). [Google Scholar]
  • [22].Vizzard MA, Alterations in spinal cord Fos protein expression induced by bladder stimulation following cystitis, Am J Physiol Regul Integr Comp Physiol 278 (2000) R1027–1039. [DOI] [PubMed] [Google Scholar]
  • [23].Wang F, Shen X, Guo X, Peng Y, Liu Y, Xu S, Yang J, Spinal macrophage migration inhibitory factor contributes to the pathogenesis of inflammatory hyperalgesia in rats, Pain 148 (2010) 275–283. [DOI] [PubMed] [Google Scholar]
  • [24].Wang F, Xu S, Shen X, Guo X, Peng Y, Yang J, Spinal macrophage migration inhibitory factor is a major contributor to rodent neuropathic pain-like hypersensitivity, Anesthesiology 114 (2011) 643–659. [DOI] [PubMed] [Google Scholar]
  • [25].Wang YS, Li YY, Wang LH, Kang Y, Zhang J, Liu ZQ, Wang K, Kaye AD, Chen L, Tanshinone IIA Attenuates Chronic Pancreatitis-Induced Pain in Rats via Downregulation of HMGB1 and TRL4 Expression in the Spinal Cord, Pain Physician 18 (2015) E615–628. [PubMed] [Google Scholar]

RESOURCES